NuVasive to Present at ROTH 21st Annual OC Growth Stock ...( SAN DIEGO Feb. 10 /- NuVasive Inc. (N...),Health

SAN DIEGO, Feb. 10 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Kevin O'Boyle, Executive Vice President & Chief Financial Officer, is scheduled to present at the ROTH 21st Annual OC Growth Stock Conference at The Ritz-Carlton Hotel in Laguna Niguel, California on Tuesday, February 17, 2009, at 11:30 a.m. PT.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surg
'/>"/>